Antibacterial compounds and methods for use

Patent metadata

Field	Value
Publication number	US-9409905-B2
Application number	US-201214241506-A
Country	US
Kind code	B2
Filing date	Aug 29, 2012
Priority date	Aug 29, 2011
Publication date	Aug 9, 2016
Grant date	Aug 9, 2016

Abstract

The present description relates to compounds and forms and pharmaceutical compositions thereof and methods for use thereof to treat or ameliorate bacterial infections caused by wild-type and multi-drug resistant Gram-negative and Gram-positive pathogens.

First claim

What is claimed is:

1. A compound of Formula (I):

or a form thereof, wherein
R 1 is aryl, heterocyclyl or heteroaryl each optionally substituted with one, two or three substituents each selected from R 5 and one additional substituent selected from R 6 , wherein aryl and heteroaryl are selected from a bicyclic or tricyclic ring system, and wherein heterocyclyl is selected from the group consisting of dihydro-indolyl, indolinyl, tetrahydro-indolyl, dihydro-indazolyl, tetrahydro-indazolyl, dihydro-isoindolyl, dihydro-benzofuranyl, tetrahydro-benzofuranyl, dihydro-benzothienyl, tetrahydro-benzothienyl, dihydro-benzimidazolyl, tetrahydro-benzimidazolyl, dihydro-benzooxazolyl, 2,3-dihydrobenzo[d]oxazolyl, tetrahydro-benzooxazolyl, dihydro-benzooxazinyl, 3,4-dihydro-2H-benzo[b][1,4]oxazinyl, tetrahydro-benzooxazinyl, dihydro-purinyl, tetrahydro-purinyl, dihydro-quinolinol, tetrahydro-quinolinyl, 1,2,3,4-tetrahydroquinolinyl, dihydro-isoquinolinyl, 3,4-dihydroisoquinolin-(1H)-yl, tetrahydro-isoquinolinyl, 1,2,3,4-tetrahydroisoquinolinyl, dihydro-quinazolinyl, tetrahydro-quinazolinyl, dihydro-quinoxalinyl, tetrahydro-quinoxalinyl, 1,2,3,4-tetrahydroquinoxalinyl, 2,5-dihydro-1H-pyrrolyl, hexahydropyrrolo[3,4-b][1,4]oxazin-(2H)-yl, (4aR,7aS)-hexahydropyrrolo[3,4-b][1,4]oxazin-(4aH)-yl, 3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazinyl, (cis)-octahydrocyclopenta[c]pyrrolyl, hexahydropyrrolo[3,4-b]pyrrol-(1H)-yl, (3aR,6aR)-hexahydropyrrolo[3,4-b]pyrrol-(1H)-yl, (3aR,6aS)-hexahydropyrrolo[3,4-c]pyrrol-(1H)-yl, 5H-pyrrolo[3,4-b]pyridin-(7H)-yl, 5,7-dihydro-6Hpyrrolo[3,4-b]pyridinyl, tetrahydro-1H-pyrrolo[3,4-b]pyridin-(2H,7H,7aH)-yl, hexahydro-1H-pyrrolo[3,4-b]pyridin-(2H)-yl, (4aR,7aR)-hexahydro-1H-pyrrolo[3,4-b]pyridin-(2H)-yl, octahydro-6H-pyrrolo[3,4-b]pyridinyl, 2,3,4,9-tetrahydro-1H-carbazolyl, 1,2,3,4-tetrahydropyrazino[1,2-a]indolyl, 2,3-dihydro-1H-pyrrolo[1,2-a]indolyl, (3aR,6aR)-hexahydrocyclopenta[c]pyrrol-(1H)-yl, (3aR,4R,6aS)-hexahydrocyclopenta[c]pyrrol-(1H)-yl, (3aR,4S,6aS)-hexahydrocyclopenta[c]pyrrol-(1H)-yl, (3aR,5r,6aS)-hexahydrocyclopenta[c]pyrrol-(1H)-yl, 1,3-dihydro-2H-isoindolyl, octahydro-2H-isoindolyl, (3aS)-1,3,3a,4,5,6-hexahydro-2H-isoindolyl, (3aR,4R,7aS)-1H-isoindol-(3H,3aH,4H,5H,6H,7H,7aH)-yl, (3aR,7aS)-octahydro-2H-isoindolyl, (3aR,4R,7aS)-octahydro-2H-isoindolyl, (3aR,4S,7aS)-octahydro-2H-isoindolyl, 2,5-diazabicyclo[2.2.1]heptanyl, 2-azabicyclo[2.2.1]hept-5-enyl, 3-azabicyclo[3.1.0]hexanyl, 3,6-diazabicyclo[3.1.0]hexanyl, (1R,5S,6s)-3-azabicyclo[3.1.0]hexanyl, (1S,5R,6R)-3-azabicyclo[3.2.0]heptanyl, (1S,5R,6S)-3-azabicyclo[3.2.0]heptanyl, 5-azaspiro[2.4]heptanyl, 2,6-diazaspiro[3.3]heptanyl, 2,5-diazaspiro[3.4]octanyl, 2,6-diazaspiro[3.4]octanyl, 2,7-diazaspiro[3.5]nonanyl, 2,7-diazaspiro[4.4]nonanyl, 2-azaspiro[4.5]decanyl, 2,8-diazaspiro[4.5]decanyl, 6,7,8,9-tetrahydropyrido[1,2-a]indolyl, 2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indolyl and 2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indolyl;
R 2 is fluorine, chlorine, iodine, cyano, C 1-8 alkyl, halo-C 1-8 alkyl, hydroxyl-C 1-8 alkyl, formyl-C 1-8 alkyl, C 1-8 alkoxy-C 1-8 alkyl, C 2-8 alkenyl, C 2-8 alkynl, carboxy, amino, C 1-8 alkyl-amino, (C 1-8 alkyl) 2 -amino, amino-C 1-8 alkyl, C 1-8 alkyl-amino-C 1-8 alkyl, (C 1-8 alkyl) 2 -amino-C 1-8 alkyl, C 3-14 cycloalkyl, C 3-8 cycloalkyl-oxy or aryl-C 1-8 alkyl, wherein each instance of aryl is optionally substituted with one halogen substituent;
R 3 is hydrogen, halogen, hydroxyl, C 1-8 alkyl, C 1-8 alkoxy, carboxyl, amino, C 1-8 alkyl-amino, (C 1-8 alkyl) 2 -amino or C 1-8 alkyl-SO 2 -amino;
R 4 is hydrogen;
R 5 is halogen, hydroxyl, oxo, cyano, nitro, C 1-8 alkyl, hydroxyl-C 1-8 alkyl, halo-C 1-8 alkyl, C 1-8 alkoxy, C 1-8 alkyl-thio, carboxyl, C 1-8 alkyl-carbonyl, C 1-8 alkoxy-carbonyl, amino-carbonyl, amino, C 1-8 alkyl-amino, (C 1-8 alkyl) 2 -amino, C 2-8 alkenyl-amino, (C 2-8 alkenyl) 2 -amino, C 2-8 alkynyl-amino, (C 2-8 alkynyl) 2 -amino, amino-C 1-8 alkyl, C 1-10 alkyl-amino-C 1-8 alkyl, (C 1-8 alkyl) 2 -amino-C 1-8 alkyl, C 2-8 alkenyl-amino-C 1-8 alkyl, (C 2-8 alkenyl) 2 -amino-C 1-8 alkyl, C 2-8 alkynyl-amino-C 1-8 alkyl, (C 2-8 alkynyl) 2 -amino-C 1-8 alkyl, halo-C 1-8 alkyl-amino, (halo-C 1-8 alkyl) 2 -amino, halo-C 1-8 alkyl-amino-C 1-8 alkyl, (halo-C 1-8 alkyl) 2 -amino-C 1-8 alkyl, C 1-8 alkoxy-C 1-8 alkyl-amino, (C 1-8 alkoxy-C 1-8 alkyl, C 1-8 alkyl)-amino, (C 1-8 alkoxy-C 1-8 alkyl) 2 -amino, C 1-8 alkoxy-C 1-8 alkyl-amino-C 1-8 alkyl, (C 1-8 alkoxy-C 1-8 alkyl, C 1-8 alkyl)-amino-C 1-8 alkyl, (C 1-8 alkoxy-C 1-8 alkyl) 2 -amino-C 1-8 alkyl, amino-C 1-8 alkyl-amino, (amino-C 1-8 alkyl, C 1-8 alkyl)amino, C 1-8 alkyl-amino-C 1-8 alkyl-amino, (C 1-8 alkyl-amino-C 1-8 alkyl, C 1-8 alkyl)amino, (C 1-8 alkyl) 2 -amino-C 1-8 alkyl-amino, [(C 1-8 alkyl) 2 -amino-C 1-8 alkyl, C 1-8 alkyl]amino, amino-C 1-8 alkyl-amino-C 1-8 alkyl, (amino-C 1-8 alkyl, C 1-8 alkyl)amino-C 1-8 alkyl, C 1-8 alkyl-amino-C 1-8 alkyl-amino-C 1-8 alkyl, (C 1-8 alkyl-amino-C 1-8 alkyl, C 1-8 alkyl)amino-C 1-8 alkyl, (C 1-8 alkyl) 2 -amino-C 1-8 alkyl-amino-C 1-8 alkyl, [(C 1-8 alkyl) 2 -amino-C 1-8 alkyl, C 1-8 alkyl]amino-C 1-8 alkyl, hydroxyl-amino, hydroxyl-C 1-8 alkyl-amino, (hydroxyl-C 1-8 alkyl, C 1-8 alkyl)amino, (hydroxyl-C 1-8 alkyl) 2 -amino, hydroxyl-C 1-8 alkyl-amino-C 1-8 alkyl, (hydroxyl-C 1-8 alkyl, C 1-8 alkyl)amino-C 1-8 alkyl, hydroxyl-C 1-8 alkyl-amino-C 1-8 alkyl-amino, (hydroxyl-C 1-8 alkyl-amino-C 1-8 alkyl, C 1-8 alkyl)amino, (hydroxyl-C 1-8 alkyl, C 1-8 alkyl)amino-C 1-8 alkyl-amino, [(hydroxyl-C 1-8 alkyl, C 1-8 alkyl)amino-C 1-8 alkyl, C 1-8 alkyl]amino, (C 1-8 alkyl-carbonyl, C 1-8 alkyl)amino-C 1-8 alkyl, C 1-8 alkyl-amino-carbonyl, (C 1-8 alkyl) 2 -amino-carbonyl or (C 1-8 alkyl) 2 -amino-carbonyl-C 1-8 alkyl-amino-C 1-8 alkyl;
R 6 is C 3-14 cycloalkyl, C 3-14 cycloalkyl-C 1-8 alkyl, C 3-14 cycloalkyl-oxy, C 3-14 cycloalkyl-C 1-8 alkoxy, C 3-14 cycloalkyl-amino, C 3-14 cycloalkyl-amino-C 1-8 alkyl, (C 3-14 cycloalkyl, C 1-8 alkyl)amino-C 1-8 alkyl, (C 3-14 cycloalkyl) 2 -amino-C 1-8 alkyl, C 3-14 cycloalkyl-C 1-8 alkyl-amino-C 1-8 alkyl, (C 3-14 cycloalkyl-C 1-8 alkyl, C 1-8 alkyl)amino-C 1-8 alkyl, (C 3-14 cycloalkyl-C 1-8 alkyl) 2 -amino-C 1-8 alkyl, aryl, aryl-C 1-8 alkyl, aryl-C 1-8 alkoxy, aryl-amino, (aryl,C 1-8 alkyl)amino, (aryl) 2 -amino, aryl-amino-C 1-8 alkyl, (aryl,C 1-8 alkyl)amino-C 1-8 alkyl, (aryl) 2 -amino-C 1-8 alkyl, aryl-C 1-8 alkyl-amino, (aryl-C 1-8 alkyl, C 1-8 alkyl)amino, (aryl-C 1-8 alkyl) 2 -amino, aryl-C 1-8 alkyl-amino-C 1-8 alkyl, (aryl-C 1-8 alkyl, C 1-8 alkyl)amino-C 1-8 alkyl, (aryl-C 1-8 alkyl) 2 -amino-C 1-8 alkyl, heteroaryl, heteroaryl-C 1-8 alkyl, heteroaryl-amino, heteroaryl-C 1-8 alkyl-amino, (heteroaryl-C 1-8 alkyl, C 1-8 alkyl)amino, (heteroaryl-C 1-8 alkyl) 2 -amino, heteroaryl-C 1-8 alkyl-amino-C 1-8 alkyl, (heteroaryl-C 1-8 alkyl, C 1-8 alkyl)amino-C 1-8 alkyl, heterocyclyl, heterocyclyl-C 1-8 alkyl, heterocyclyl-oxy, heterocyclyl-C 1-8 alkoxy, heterocyclyl-amino, (heterocyclyl, C 1-8 alkyl)amino, (heterocyclyl) 2 -amino, heterocyclyl-amino-C 1-8 alkyl, (heterocyclyl, C 1-8 alkyl)amino-C 1-8 alkyl, (heterocyclyl) 2 -amino-C 1-8 alkyl, (heterocyclyl, C 3-14 cycloalkyl-C 1-8 alkyl)amino-C 1-8 alkyl, heterocyclyl-C 1-8 alkyl-amino-C 1-8 alkyl, (heterocyclyl-C 1-8 alkyl, C 1-8 alkyl)amino-C 1-8 alkyl, (heterocyclyl-C 1-8 alkyl) 2 -amino-C 1-8 alkyl, heterocyclyl-oxy-amino, (heterocyclyl-oxy, C 1-8 alkyl)amino, (heterocyclyl-oxy) 2 -amino, (heterocyclyl-oxy-C 1-8 alkyl, C 1-8 alkyl)amino, heterocyclyl-carbonyl or heterocyclyl-carbonyl-oxy;
wherein each instance of heterocyclyl is optionally substituted with one, two or three substituents each selected from R 7 ; and,
wherein each instance of C 3-14 cycloalkyl, aryl and heteroaryl is opti

Assignees

• Branstrom Arthur
• Josyula Vara Prasad Venkata Nagendra
• Arnold Michael Andrew
• Gerasyuto Aleksey I
• Karp Gary
• Wang Jiashi
• Baird John David
• Chen Guangming
• Ginzburg Olya
• Narasimhan Jana
• Peddi Srinivasa
• Qi Hongyan
• Smith Sean Wesley
• Woll Matthew G
• Yang Tianle
• Zhang Nanjing
• Zhang Xiaoyan
• Ptc Therapeutics Inc

Inventors

• Branstrom Arthur
• Josyula Vara Prasad Venkata Nagendra
• Arnold Michael Andrew
• Gerasyuto Aleksey I
• Karp Gary
• Wang Jiashi
• Baird John David
• Chen Guangming
• Ginzburg Olya
• Narasimhan Jana
• Peddi Srinivasa
• Qi Hongyan
• Smith Sean Wesley
• Woll Matthew G
• Yang Tianle
• Zhang Nanjing
• Zhang Xiaoyan

Classifications

• C07D401/04

  directly linked by a ring-member-to-ring-member bond · CPC title

• A61P31/04

  Antibacterial agents · CPC title

• C07D405/14

  containing three or more hetero rings · CPC title

• A61K31/5377

  not condensed and containing further heterocyclic rings, e.g. timolol · CPC title

• A61K31/437

  the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline · CPC title